Shaily Engineering Plastics Limited, established in 1987, is a prominent player in the plastics industry, recognized as India's largest exporter of plastic components. The company provides integrated, end-to-end solutions, from product design and development to manufacturing and delivery. With a workforce of over 2,000 employees spread across seven facilities in Gujarat, Shaily operates a significant manufacturing base equipped with more than 200 injection molding machines. The company's business model is de-risked through diversification across three core segments. The Consumer segment caters to home furnishings, FMCG packaging, LED lighting, toys, and carbon steel furniture. The Industrial segment serves the automotive and appliance sectors with high-performance engineering components. The Healthcare segment, a key growth driver, focuses on platform devices, complex drug delivery systems like pen injectors, and pharmaceutical packaging, operating from a dedicated ISO Class 8 clean room facility. Shaily's long-standing relationships with marquee global clients underscore its reputation for quality and reliability. The company is led by an experienced management team, including Executive Chairman Mr. Mahendra Sanghvi and Managing Director Mr. Amit Sanghvi, supported by a board of executive and independent directors.

Official Website: https://shaily.com/

• Revenue Performance: The company reported strong consolidated revenue growth of 27% year-over-year (YoY) for Q3 FY26, reaching Rs. 250.5 crores. For the nine months (9M) of FY26, revenue increased by 32% YoY to Rs. 753.8 crores. This growth demonstrates robust demand for the company's products.

• Profitability Growth: Profitability metrics showed exceptional improvement. Consolidated EBITDA for Q3 FY26 grew by 43% YoY to Rs. 66.4 crores, while Profit After Tax (PAT) increased by 48% YoY to Rs. 37.4 crores. The 9M FY26 performance was even stronger, with EBITDA surging 76% and PAT growing 101% YoY.

• Margin Expansion: A significant driver of the financial performance was margin expansion. The consolidated Gross Profit Margin expanded by a substantial 1,090 basis points (bps) YoY to 58.4% in Q3 FY26. Consequently, the EBITDA margin improved by 310 bps to 26.5%, and the PAT margin grew by 220 bps to 14.9% for the same period.

• Capital Efficiency: The company has demonstrated improved use of capital. Return on Capital Employed (RoCE) increased from 24.4% in March 2025 to 38.4% in December 2025. Similarly, Return on Equity (RoE) rose from 18.5% to 29.1% over the same period.

• Balance Sheet Strength: The company's financial position strengthened, with the Total Debt to Equity ratio reducing from 0.4x in March 2025 to 0.3x in December 2025, indicating a healthier and less leveraged balance sheet.

The company's financial results for the period reflect strong execution, characterized by robust revenue growth, exceptional profitability improvements, and enhanced capital efficiency.

• Market Leadership: Shaily is distinguished as India's largest exporter of plastics components, giving it significant scale and global market access.

• Diversified Business Model: The company operates a de-risked model by serving three distinct segments: Consumer, Healthcare, and Industrial. This diversification mitigates dependency on any single industry and allows it to capture growth across different economic cycles.

• High-Value Product Focus: The company's capabilities extend to complex, high-precision products, particularly in the healthcare sector (e.g., drug delivery devices), which command higher margins and have high entry barriers.

• Strong Client Relationships: Shaily has established long-standing relationships with marquee global clients, which ensures a stable revenue base and speaks to its quality and reliability as a supply chain partner.

• Financial Credibility: The company holds strong credit ratings of CARE A+ for long-term facilities and CARE A1 for short-term facilities, affirming its financial stability and disciplined management.

Shaily's market leadership as an exporter, combined with a diversified, high-value business model and strong financial credibility, provides a unique and resilient operational framework.

• Healthcare Segment as the Primary Driver: The Healthcare segment is the principal engine of growth. Its revenue surged by 139% YoY in Q3 FY26 to Rs. 104.3 crores and 158% YoY for 9M FY26. This segment now constitutes 42% of total revenue in Q3 FY26, up from 22% in Q3 FY25.

• Shift to Higher Value Products: While the total volume of polymers processed decreased by 12% YoY in Q3 FY26, revenue grew by 27%. This divergence clearly indicates a successful strategic shift in the product mix towards higher-value, more complex components, primarily within the healthcare vertical.

• Strong Export Growth: Exports are a key contributor to growth, with their share of revenue increasing from 20.6% in Q3 FY25 to 28.7% in Q3 FY26. This reflects growing demand from international markets.

• Industrial Segment Growth: The Industrial segment also posted a healthy 87% YoY revenue growth in Q3 FY26, contributing to the overall positive performance.

• Consumer Segment Contraction: The Consumer segment, historically a large contributor, experienced a 13% YoY decline in revenue for Q3 FY26. However, its reduced contribution was more than offset by the phenomenal growth in other segments.

The company's growth is being propelled by a strategic pivot to the high-value healthcare segment and a strengthening export business, which is effectively compensating for weakness in the consumer vertical.

• GLP-1 Drug Delivery Market: The company is strategically positioned to capitalize on the fast-growing global GLP-1 market for diabetes and weight-loss drugs. It has already onboarded two new customers in this segment and signed two new contracts for the manufacture of pen injectors.

• International Expansion: The planned facility in Abu Dhabi represents a significant opportunity to expand its global manufacturing footprint. This move will enhance proximity to international customers and directly support the global demand for drug delivery devices.

• New Customer and Product Wins: The company continues to demonstrate its ability to win new business. Recent successes include securing a new customer for Power Tool components in the Industrial segment and a new product mandate from an existing client in the home furnishing space.

Shaily is actively pursuing substantial opportunities in the global healthcare market, particularly in drug delivery devices, while strategically expanding its international presence to support this growth.

• Capacity Utilization: The average machine utilization across all plants stood at 47.1% in Q3 FY26, an increase of 250 bps from 44.6% in Q3 FY25. For the nine-month period, utilization improved by 510 bps to 47.8%. This indicates that the company has significant existing capacity to accommodate further volume growth without immediate major investments in its current facilities.

• Strategic Capex for Future Growth: The company is undertaking a major capital expenditure project to set up a new manufacturing facility in Abu Dhabi.

• Investment: The planned investment is between AED 130–150 million.

• Purpose: This facility will focus on manufacturing medical devices, specifically pen injectors.

• Added Capacity: It is expected to have a capacity to produce approximately 75 million pen injectors annually.

The company is currently operating with ample spare capacity for near-term growth while making a significant strategic investment in a new international facility to secure long-term opportunities.

• Abu Dhabi Medical Device Facility: The company's primary stated future plan is the establishment of a greenfield manufacturing plant in Abu Dhabi.

• Strategic Rationale: This expansion is designed to build scalable capacity in the high-growth drug-delivery segment, move production closer to key international customers, and capitalize on the global GLP-1 opportunity.

• Project Timeline: The facility is expected to become operational in Q4 FY28.

• Government Support: The company is actively engaged in discussions with the Abu Dhabi Investment Office (ADIO) to explore potential financial support for this strategic project.

The company's forward-looking strategy is centered on a major global expansion with a new facility in Abu Dhabi, aimed at cementing its position in the high-value medical device market.

• Gross Margin Expansion: The company achieved a remarkable expansion in its consolidated Gross Profit Margin, which surged by 1,090 bps YoY to 58.4% in Q3 FY26. This was the primary driver for overall profitability improvement.

• Operating and Net Margin Growth: The improved gross margin translated down the income statement. The consolidated EBITDA margin increased by 310 bps YoY to 26.5% in Q3 FY26. The PAT margin also expanded by 220 bps YoY to 14.9%.

• Favorable Product Mix: The key reason for this significant margin accretion is the change in the revenue mix. The sharp increase in the share of high-margin business from the healthcare segment, coupled with a decline in the relatively lower-margin consumer business, has structurally improved the company's profitability profile.

The company has successfully executed a strategy that has led to substantial, across-the-board margin expansion, driven primarily by an improved product mix favoring the highly profitable healthcare segment.

• General Market and Economic Risks: The company is exposed to broad economic risks, including the performance of the Indian and global economies, which could impact demand across its segments. It also faces risks from industry-wide competition and technological changes.

• Execution Risk: Future performance depends on the company's ability to successfully implement its growth strategy, particularly the large-scale international expansion in Abu Dhabi, and manage its expansion effectively.

• Segment Concentration and Decline: While the healthcare segment's growth is currently very strong, the 13% YoY revenue decline in the Consumer segment is a point of concern. Over-reliance on the healthcare segment could pose a risk if growth in that vertical slows unexpectedly.

Key risks include macroeconomic headwinds and project execution challenges, alongside a notable decline in the consumer business that increases reliance on the healthcare segment's continued outperformance.

• Strengthening Healthcare Leadership: The company has appointed Mr. Joe Kam as the Chief Operating Officer (COO) for its Healthcare business, effective March 1, 2026. His extensive international experience, notably with industry leader SHL Medical, is expected to drive operational excellence and support the next phase of growth in this critical segment.

• New Business Wins: Shaily has secured significant new business across its verticals:

• Healthcare: Signed two new contracts with global companies for pen injectors and onboarded two new customers in the rapidly growing GLP-1 segment.

• Industrial: Acquired a new customer for the supply of Power Tool components.

• Consumer: Received a new product mandate from an existing major home furnishing customer.

The company has made a strategic leadership appointment to fortify its healthcare division and has demonstrated strong commercial momentum by securing multiple new customers and contracts across all its business segments.